Heron Therapeutics, Inc. (HRTX)
After hours:
| Previous close | 1.2300 |
| Open | 1.2300 |
| Bid | 1.2100 x 2900 |
| Ask | 1.3300 x 34100 |
| Day's range | 1.1600 - 1.3400 |
| 52-week range | 0.5000 - 3.4100 |
| Volume | |
| Avg. volume | 2,892,628 |
| Market cap | 198.096M |
| Beta (5Y monthly) | 1.12 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- PR Newswire
Heron Therapeutics Announces Third Quarter 2023 Financial Results and Updates Financial Guidance
Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company focused on improving the lives of patients by developing and commercializing therapeutic innovations that improve medical care, today announced financial results for the three and nine months ended September 30, 2023 and highlighted recent corporate updates.
- PR Newswire
Heron Therapeutics to Report Third Quarter 2023 Financial Results On Tuesday, November 14, 2023
Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing and commercializing therapeutic innovations that improve medical care, today announced that the company will host a conference call and live webcast on Tuesday, November 14, 2023 at 4:30 p.m. ET to report third quarter 2023 financial results and discuss recent business highlights.
